
Online supplement to Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Therapy Use: Results from the Randomized Placebo-controlled FUTURE-2 Study, *The Journal of Rheumatology*, doi:10.3899/jrheum.160275

Supplementary Figure-1: ACR20 response rates through Week 52 in TNFi-naïve and TNFi-exposed patients





^{*}P < 0.0001; †P < 0.001; \$P < 0.01; ‡P < 0.05 vs. placebo

Missing values were imputed as non-response (non-responder imputation) at Weeks 24 and 52 ACR, American College of Rheumatology; s.c., subcutaneous; TNFi, tumor necrosis factor inhibitor

Online supplement to Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Therapy Use: Results from the Randomized Placebo-controlled FUTURE-2 Study, *The Journal of Rheumatology*, doi:10.3899/jrheum.160275

Supplementary Figure-2: ACR20 response rates in TNFi-naïve and TNFi-exposed patients with or without concomitant MTX






†P < 0.001; \$P < 0.01; †P < 0.05 vs. placebo
Missing values were imputed as non-response (non-responder imputation) at Weeks 24 and 52
ACR, American College of Rheumatology; MTX, methotrexate; s.c., subcutaneous; TNFi, tumor necrosis factor inhibitor

Online supplement to Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Therapy Use: Results from the Randomized Placebo-controlled FUTURE-2 Study, The Journal of Rheumatology, doi:10.3899/jrheum.160275

Supplementary Figure-3: ACR20 response rates in TNFi-naïve and TNFi-exposed patients stratified by body weight



10.5 10.5

Secukinumab 75 mg s.c.

Week 52

Placebo

Week 24

*P < 0.0001; $^{\dagger}P$ < 0.001; $^{\S}P$ < 0.01; $^{\ddagger}P$ < 0.05 vs. placebo Missing values were imputed as non-response (non-responder imputation) at Weeks 24 and 52 ACR, American College of Rheumatology; s.c., subcutaneous; TNFi, tumor necrosis factor inhibitor

Week 52

Secukinumab 150 mg s.c.

11.8


N=17

Secukinumab 300 mg s.c.

Week 24

Online supplement to Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Therapy Use: Results from the Randomized Placebo-controlled FUTURE-2 Study, *The Journal of Rheumatology*, doi:10.3899/jrheum.160275

Supplementary Figure-4: ACR20 response rates in TNFi-naïve and TNFi-exposed patients stratified by baseline disease activity



^{*}P < 0.0001; \$P < 0.01; ‡P < 0.05 vs. placebo

Secukinumab 300 mg s.c.

Missing values were imputed as non-response (non-responder imputation) at Weeks 24 and 52

ACR, American College of Rheumatology; DAS28-CRP, 28-joint Disease Activity Score using C-Reactive Protein; s.c., subcutaneous;

Secukinumab 150 mg s.c.

Secukinumab 75 mg s.c.

Placebo

TNFi, tumor necrosis factor inhibitor